Treatment Overview
Hormone therapy in India, also called endocrine therapy or hormonal therapy, is a systemic cancer treatment that blocks hormones or reduces their production when those hormones are helping cancer cells grow. It is particularly important in hormone-sensitive cancers, especially hormone receptor-positive breast cancer and prostate cancer.
Depending on the cancer, hormone therapy may be used after surgery, alongside radiation therapy, before surgery in selected patients, or as a major treatment for recurrent or metastatic disease. In India it is available through medical oncology and multidisciplinary cancer centres. Treatment is selected according to the cancer type, stage, hormone-receptor status, previous treatment, menopausal status, overall health and other biomarkers.
There is a named GAF Healthcare partner planning sheet for hormone therapy: $1,000–$4,500, typically Outpatient · often years of tablets. Neighbouring United States comparison figures on the same sheet are $5,000–$25,000. That India band is a pathway planning range for oncology review, the named medicine and associated monitoring. It is not the price of a single tablet and it is not a whole-cancer package.
Neighbouring chemotherapy is $1,500–$8,000+, typically Outpatient cycles · 3–6 months typical. Neighbouring targeted therapy is $8,000–$30,000, typically oral or infusion · months of therapy. Neighbouring molecular targeted therapy is $10,000–$32,000, typically Oral or infusion by mutation. Neighbouring precision oncology is $2,000–$7,000, typically NGS panel + clinic visit. Neighbouring immunotherapy is $15,000–$45,000. Neighbouring adjuvant chemotherapy is $2,500–$10,000. Neighbouring neoadjuvant chemotherapy is $2,500–$10,000.
Disease pathways sit on breast cancer treatment in India, prostate cancer treatment in India, ovarian cancer treatment in India, radical prostatectomy in India and breast reconstruction in India. Neighbouring systemic lists sit on molecular targeted therapy in India, precision oncology in India, adjuvant chemotherapy in India and neoadjuvant chemotherapy in India. Radiation neighbours include external beam radiotherapy in India, IMRT in India, IGRT in India, SBRT in India, stereotactic radiosurgery in India, proton beam therapy in India and brachytherapy in India. There is no live GAF endometrial-cancer-only, lung-cancer-only or gastric-cancer-only treatment page.
Important: Hormone therapy for cancer is not the same as menopausal hormone replacement therapy. Cancer hormone therapy is intended to block or reduce hormones that cancer cells use for growth. A quotation should be obtained only after records review.
What is hormone therapy?
Hormone therapy is a type of systemic cancer treatment, meaning the medicine can act throughout the body rather than only at the original tumour site.
Some cancer cells depend on naturally occurring hormones to grow. For example:
- Some breast cancers use estrogen and/or progesterone. See breast cancer treatment in India and hormone therapy for breast cancer.
- Prostate cancer commonly depends on androgens, particularly testosterone. See prostate cancer treatment in India and hormone therapy for prostate cancer.
- Some endometrial cancers may respond to hormonal treatment when their tumour biology makes them hormone-sensitive. There is no live GAF endometrial-cancer-only treatment page.
- Selected ovarian tumours may be considered for endocrine approaches. See ovarian cancer treatment in India.
Hormone therapy works by either:
- Reducing the amount of a hormone available to cancer cells, or
- Blocking the hormone from acting on the cancer cell, or
- Interfering with the hormone receptor or pathway that sends growth signals.
The exact approach depends on the type of cancer and its molecular characteristics.
Hormone therapy versus hormone replacement therapy
These two terms can sound similar, but they are not the same treatment.
Hormone therapy for cancer is intended to block or reduce hormones that cancer cells use for growth.
Hormone replacement therapy, such as menopausal hormone therapy, is used to replace hormones that the body is no longer producing adequately.
The two treatments have very different purposes and should not be confused. This distinction is particularly important for people searching for “hormone therapy” after menopause. Menopausal hormone therapy has its own benefits, risks and contraindications and should be discussed with an appropriate physician.
Which cancers can be treated with hormone therapy?
Hormone therapy is most strongly associated with:
| Cancer | Role of hormone therapy |
|---|---|
| Breast cancer | Major treatment for hormone receptor-positive disease |
| Prostate cancer | Major treatment for androgen-sensitive disease |
| Endometrial cancer | Used in selected hormone-sensitive cancers |
| Other hormone-sensitive cancers | May have a role in selected circumstances |
The presence of a hormone receptor or another relevant biological pathway does not automatically mean that hormone therapy will be the only treatment.
Cancer treatment is often multimodal and may combine surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy and hormone therapy depending on the individual case. Neighbouring matched-medicine lists sit on molecular targeted therapy in India. Genomic-testing lists sit on precision oncology in India. Named immunotherapy lists sit on Immunotherapy in India.
Hormone therapy for breast cancer in India
Hormone therapy is an important component of treatment for hormone receptor-positive breast cancer.
Breast cancer tissue is generally tested for hormone receptors, particularly:
- Estrogen receptor (ER)
- Progesterone receptor (PR)
If cancer cells contain these receptors, the cancer may be classified as hormone receptor-positive (HR-positive). Hormone therapy can then be used to reduce the effect of estrogen or interfere with estrogen signalling.
According to the National Cancer Institute, approximately 80% of breast cancers are hormone receptor-positive, although the exact proportion can vary by population and study. HER2 status is a separate decision. See HER2-positive breast cancer.
When is hormone therapy used for breast cancer?
Hormone therapy may be recommended:
- After breast cancer surgery
- Before surgery in selected patients
- To reduce the risk of recurrence
- For recurrent breast cancer
- For advanced or metastatic hormone receptor-positive breast cancer
- In some cases of male breast cancer
The treatment plan depends on menopausal status, tumour stage, receptor status, previous treatments and other clinical factors. Reconstruction questions sit on breast reconstruction in India. Chemotherapy neighbours sit on adjuvant chemotherapy in India, neoadjuvant chemotherapy in India and chemotherapy for breast cancer.
Hormone therapy drugs for breast cancer
Several categories of endocrine therapy are used.
1. Tamoxifen
Tamoxifen is a selective estrogen receptor modulator (SERM). It blocks estrogen signalling in breast tissue and has been used extensively in both premenopausal and postmenopausal patients. Tamoxifen may be prescribed after surgery to reduce recurrence risk or in other settings of hormone receptor-positive disease.
2. Aromatase inhibitors
Aromatase inhibitors reduce estrogen production by blocking the aromatase enzyme. Common medicines include:
- Letrozole
- Anastrozole
- Exemestane
They are particularly important in postmenopausal breast cancer. In premenopausal patients, an aromatase inhibitor generally requires ovarian suppression because functioning ovaries can continue producing substantial estrogen.
3. Ovarian suppression
For some premenopausal patients, doctors may recommend temporarily suppressing ovarian function. Medicines such as goserelin and leuprolide can suppress ovarian hormone production. Ovarian function can also be permanently stopped through surgery, known as oophorectomy, in selected situations.
4. Selective estrogen receptor degraders
Selective estrogen receptor degraders, or SERDs, act directly on the estrogen receptor. Examples include fulvestrant and other newer oral SERDs in appropriate clinical settings. Their use depends on the cancer’s stage, previous treatment and molecular characteristics.
How long is hormone therapy given for breast cancer?
Hormone therapy is often a long-term treatment.
For early hormone receptor-positive breast cancer, treatment commonly extends for at least five years, although some patients may be advised to continue for longer depending on their recurrence risk and treatment history.
The final duration should not be determined by the number of years alone. Your oncologist may consider tumour size, lymph-node involvement, stage, menopausal status, receptor status, previous endocrine treatment, tolerance and side effects, risk of recurrence and other medical conditions.
Hormone therapy for prostate cancer in India
Hormone therapy has a major role in the treatment of prostate cancer.
Unlike breast cancer, where estrogen and progesterone are central to many hormone-sensitive tumours, prostate cancer is commonly driven by androgens, particularly testosterone and dihydrotestosterone (DHT). Hormone therapy for prostate cancer is therefore commonly called androgen deprivation therapy (ADT).
ADT reduces androgen production or blocks androgen activity, thereby interfering with signals that encourage prostate cancer cells to grow. Named surgical lists sit on radical prostatectomy in India.
How does hormone therapy work for prostate cancer?
There are two broad strategies.
Reduce androgen production
This can be achieved with GnRH/LHRH agonists, other androgen-deprivation approaches, or orchiectomy in selected circumstances.
Block androgen activity
Androgen-receptor-targeting medicines prevent testosterone or related hormones from activating the androgen receptor. Examples include enzalutamide, apalutamide, darolutamide and bicalutamide in selected settings. Other medicines, such as abiraterone, interfere with androgen production.
When is hormone therapy used for prostate cancer?
Depending on the clinical situation, hormone therapy may be used:
- With radiation therapy for selected higher-risk localised prostate cancer
- For recurrent prostate cancer
- For biochemical recurrence in selected patients
- For locally advanced prostate cancer
- For metastatic prostate cancer
- For hormone-sensitive advanced disease
- As continuing androgen suppression in castration-resistant disease, together with additional treatments as appropriate
Modern prostate cancer management frequently uses combination approaches rather than hormone therapy alone in advanced disease. Radiation neighbours include external beam radiotherapy in India, IMRT in India, IGRT in India, SBRT in India and brachytherapy in India.
What is castration-sensitive prostate cancer?
Castration-sensitive prostate cancer is prostate cancer that continues to respond to treatment that lowers androgen levels. The cancer may be newly diagnosed, recurrent, locally advanced or metastatic. Hormone therapy can slow cancer growth in this setting.
What is castration-resistant prostate cancer?
Some prostate cancers eventually progress despite testosterone being reduced to very low levels. This is called castration-resistant prostate cancer (CRPC).
Importantly, “castration-resistant” does not mean that all hormonal treatment stops working. Modern androgen-receptor-targeting and androgen-synthesis treatments may still have an important role, depending on the disease and previous treatment.
Hormone therapy for endometrial cancer
Hormone therapy may be used in selected endometrial cancers, particularly when the tumour has biological characteristics suggesting that it may respond to hormonal treatment.
The National Cancer Institute notes that hormone therapy works by removing hormones or blocking their action when cancer cells have hormone receptors.
It may be considered in particular clinical circumstances, including some patients with recurrent, advanced or fertility-preservation-related disease, depending on pathology and other factors. It is not appropriate for every endometrial cancer.
Treatment selection depends on histological type, grade, stage, hormone receptor status, molecular characteristics, previous treatment and overall health. There is no live GAF endometrial-cancer-only treatment page.
Is hormone therapy used for ovarian cancer?
Hormonal approaches can have a role in selected ovarian cancers, but they are not a standard treatment for every ovarian cancer.
The tumour subtype and molecular characteristics are important. Patients should therefore not assume that an ovarian cancer diagnosis automatically means hormone therapy is appropriate. See ovarian cancer treatment in India.
Hormone therapy before or after surgery
Hormone therapy can be used at different stages of cancer treatment.
Neoadjuvant hormone therapy is given before surgery. The purpose may be to control or shrink a hormone-sensitive tumour and potentially make subsequent local treatment more feasible in selected situations. Neighbouring cytotoxic lists sit on neoadjuvant chemotherapy in India.
Adjuvant hormone therapy is given after surgery. In hormone receptor-positive breast cancer, endocrine therapy after surgery is commonly used to reduce the risk of recurrence. Neighbouring cytotoxic lists sit on adjuvant chemotherapy in India.
Treatment for recurrent or metastatic disease may use hormone therapy when cancer returns or has spread to distant organs. In these situations, the objective may be long-term disease control rather than surgical cure.
Hormone therapy with other cancer treatments
Hormone therapy does not always replace other cancer treatments.
Depending on the diagnosis, it may be combined with:
- Surgery
- Chemotherapy
- Radiation therapy
- Targeted therapy
- Immunotherapy
- Other systemic treatments
For example, selected patients with high-risk prostate cancer receiving radiation may receive ADT as part of their treatment plan. Similarly, hormone therapy is often part of systemic treatment for HR-positive breast cancer and may be combined with targeted medicines in advanced disease.
Hormone therapy treatment process in India
The treatment journey usually begins with a detailed review of the cancer diagnosis.
Step 1: Review of medical records
The oncologist reviews the biopsy report, histopathology, imaging, previous surgery, previous chemotherapy, previous radiation therapy, previous hormone therapy, blood tests and relevant genetic or molecular reports. International patients should ideally bring digital copies of pathology and imaging reports, along with treatment summaries.
Step 2: Confirm hormone sensitivity
The doctor determines whether the cancer is likely to respond to endocrine therapy.
For breast cancer, this commonly involves ER testing, PR testing, HER2 testing and other relevant biomarkers when clinically indicated.
For prostate cancer, PSA, imaging, pathology, disease stage and other clinical characteristics are considered.
Step 3: Determine the treatment goal
The oncologist establishes whether treatment is intended to reduce recurrence risk, control locally advanced cancer, shrink a tumour before another treatment, control metastatic disease, relieve symptoms or maintain long-term disease control.
Step 4: Select the hormone therapy
The choice may depend on cancer type, stage, menopausal status, hormone receptor status, previous endocrine therapy, previous cancer treatments, other medical conditions, drug interactions, side-effect profile, treatment availability and affordability.
Step 5: Monitor treatment
Patients may undergo periodic clinical examination, blood tests, PSA testing for prostate cancer, imaging when indicated, bone-health assessment, liver-function monitoring where appropriate, lipid and metabolic monitoring and assessment of treatment-related symptoms. The monitoring schedule is individualised.
Side effects of hormone therapy
Hormone therapy does not have the same side effects as chemotherapy because the medicines work through hormonal pathways. Endocrine treatment can still produce significant side effects. The exact effects depend on the medicine and the patient’s underlying health.
Common side effects in breast cancer
Possible effects include hot flushes, night sweats, joint pain, muscle aches, fatigue, vaginal dryness, changes in menstrual function, reduced sexual interest and mood changes.
Aromatase inhibitors can be associated with joint and muscle symptoms and loss of bone density.
Tamoxifen side effects
Tamoxifen has a different side-effect profile from aromatase inhibitors. Possible effects include hot flushes, night sweats, vaginal symptoms, menstrual changes and mood changes.
Rare but important complications can include blood clots and certain uterine abnormalities. Any unusual vaginal bleeding or symptoms that concern you should be evaluated by a doctor. Chest pain, sudden breathlessness, one-sided leg swelling, collapse or heavy unexpected bleeding belongs in a local emergency department immediately. Do not wait for the next clinic appointment or use WhatsApp as emergency care.
Aromatase inhibitor side effects
Common problems may include joint stiffness, joint pain, muscle pain, hot flushes, vaginal dryness and bone loss.
Because long-term estrogen reduction can affect bone health, doctors may monitor bone density and recommend appropriate measures when indicated.
Side effects of hormone therapy for prostate cancer
Androgen deprivation can produce effects related to reduced testosterone. Possible side effects include hot flushes, reduced libido, erectile difficulties, fatigue, loss of muscle mass, weight gain, bone loss, mood changes and metabolic changes.
Long-term ADT can also affect cardiovascular and metabolic health, so monitoring should be individualised.
Can hormone therapy cause bone loss?
Yes. Some forms of endocrine therapy can reduce sex-hormone levels sufficiently to affect bone health. This is particularly relevant for long-term aromatase inhibitor therapy and long-term androgen deprivation therapy.
Your oncologist may assess fracture risk and bone mineral density and recommend measures such as exercise, calcium and vitamin D intake when appropriate, or medication for bone protection when clinically indicated. Do not begin supplements or bone medicines without discussing them with your treating team.
Does hormone therapy cause hair loss?
Hormone therapy is generally not associated with the same degree of hair loss as many chemotherapy regimens. Changes in hair thickness or texture can occur with some endocrine treatments. The effect varies significantly between individuals and medicines.
Does hormone therapy cause infertility?
It can affect reproductive function.
- Tamoxifen and ovarian suppression can affect menstrual function.
- Ovarian suppression can temporarily or permanently affect fertility depending on the treatment.
- Prostate cancer hormone therapy can substantially suppress testosterone and sexual function.
Patients who may want biological children should discuss fertility preservation before treatment begins, particularly when ovarian or testicular function may be affected.
Is hormone therapy chemotherapy?
No. Hormone therapy and chemotherapy are different types of systemic cancer treatment.
| Hormone therapy | Chemotherapy |
|---|---|
| Targets hormone-dependent cancer pathways | Uses cytotoxic medicines against rapidly dividing cells |
| Used for selected hormone-sensitive cancers | Used across many cancer types |
| Often taken for long periods | Usually administered in defined treatment cycles |
| Examples include tamoxifen and aromatase inhibitors | Examples include taxanes, platinum drugs and anthracyclines |
| Side effects are largely related to hormonal changes | Side effects depend on the chemotherapy drugs used |
Some patients may receive both treatments at different stages of their cancer journey. Neighbouring cytotoxic lists sit on adjuvant chemotherapy in India and neoadjuvant chemotherapy in India. Named chemotherapy lists sit on Chemotherapy in India.
Is hormone therapy the same as targeted therapy?
No.
Hormone therapy specifically interferes with hormone production, hormone receptors or hormone signalling.
Targeted therapy is designed to act on particular molecular abnormalities or biological pathways in cancer cells. Named targeted-therapy lists sit on Targeted Therapy in India.
There can be situations where endocrine therapy and targeted therapy are given together, particularly in advanced hormone receptor-positive breast cancer. Named lists sit on molecular targeted therapy in India. Testing lists sit on precision oncology in India.
Hormone therapy cost in India
The cost of hormone therapy in India varies considerably. There is no single price because treatment may involve an inexpensive oral medicine, a recurring injection, combination treatment or long-term therapy.
The total cost can depend on cancer type, stage, medicine selected, brand versus generic medicine, oral versus injectable treatment, treatment duration, number of treatment cycles or injections, additional targeted medicines, laboratory tests, imaging, doctor consultations and hospital or cancer-centre charges.
GAF Healthcare partner planning for hormone therapy is $1,000–$4,500, typically Outpatient · often years of tablets. Neighbouring United States comparison figures are $5,000–$25,000.
| Component | What can affect cost |
|---|---|
| Oncologist consultation | Specialist and hospital |
| Pathology/receptor testing | Tests required |
| Oral hormone medicines | Drug and brand |
| Hormone injections | Drug, dose and frequency |
| PSA or blood tests | Monitoring requirements |
| Imaging | Disease stage and clinical indication |
| Bone-density testing | Whether monitoring is required |
| Additional cancer medicines | Combination treatment |
| Follow-up | Frequency and duration |
A reliable treatment quotation should be prepared from the patient’s diagnosis and treatment plan rather than using a generic internet price. For international patients, the final estimate should ideally separate medical treatment, investigations, hospital charges and non-medical expenses.
Hormone therapy cost by Indian city
There is no reliable single national tariff. GAF Healthcare uses one national partner planning band of $1,000–$4,500 rather than inventing city-specific prices.
International patients comparing medical oncologists listing Hormone Therapy commonly start with Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. Partner medical oncology hospitals in Delhi NCR, Mumbai and Bengaluru, and in Chennai and Hyderabad, are a typical first filter. City sheets include Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. Pune, Kolkata, Ahmedabad, Kochi, Jaipur, Chandigarh, Lucknow and Varanasi are not live GAF catalog cities on this site.
| City | Catalogue doctors list | India planning band |
|---|---|---|
| Delhi NCR | Medical oncologists listing Hormone Therapy | $1,000–$4,500 |
| Mumbai | Medical oncologists listing Hormone Therapy | $1,000–$4,500 |
| Bengaluru | Medical oncologists listing Hormone Therapy | $1,000–$4,500 |
| Chennai | Medical oncologists listing Hormone Therapy | $1,000–$4,500 |
| Hyderabad | Medical oncologists listing Hormone Therapy | $1,000–$4,500 |
Why patients choose India for hormone therapy
India has established cancer centres providing medical oncology, radiation oncology, surgical oncology, pathology and molecular diagnostics.
For international patients, one potential advantage is the ability to coordinate several cancer services through multidisciplinary centres.
Depending on the patient’s needs, the treatment pathway may involve medical oncology, surgical oncology, radiation oncology, radiology, nuclear medicine, pathology, molecular diagnostics, genetic counselling, palliative care and rehabilitation.
GAF Healthcare coordinates named partner programmes in Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. The appropriate centre depends on the cancer type, receptor status and treatment complexity rather than city alone.
How to choose a centre for hormone therapy in India
Rather than choosing a hospital only by its name, patients should evaluate whether the centre can provide the complete cancer pathway they require.
Consider:
- Medical oncology expertise. Ask whether the centre has oncologists experienced in your specific cancer.
- Pathology and biomarker testing. Correct hormone-receptor assessment is essential for cancers where endocrine therapy is being considered.
- Multidisciplinary cancer care. Complex cases may require input from several specialties.
- Imaging and diagnostic services. The centre should have appropriate imaging and laboratory support.
- Access to medicines. Ask whether the prescribed medicines are routinely available at the hospital or through reliable pharmacies.
- International patient support. International patients may need assistance with medical-visa documentation, airport transfers, accommodation, interpreter services, hospital appointments, treatment coordination and follow-up after returning home.
Hospital selection should therefore be cancer-specific and receptor-specific rather than based solely on hospital reputation.
Hormone therapy for international patients coming to India
Patients travelling from Africa, the Middle East, Central Asia and other regions may be able to arrange an oncology consultation in India before travelling.
A useful medical file should include:
- Passport identification page
- Biopsy report
- Histopathology report
- ER/PR/HER2 report where relevant
- PSA reports for prostate cancer
- CT/MRI/PET-CT reports
- Imaging CDs or digital files
- Previous treatment summaries
- Previous chemotherapy records
- Radiation records
- Current medication list
- Relevant blood-test results
A specialist can then determine whether additional investigations are needed before finalising treatment.
The medical-tourism question is usually not how to stay in India for years of tablets. It is how to obtain a validated plan, begin safely and transfer prescribing and monitoring home.
Questions to ask your oncologist about hormone therapy
Before beginning treatment, consider asking:
- Is my cancer hormone-sensitive?
- Which hormone or hormone receptor is driving the cancer?
- What test confirmed hormone sensitivity?
- What is the goal of hormone therapy in my case?
- Will I need hormone therapy alone or with another treatment?
- Which medicine do you recommend?
- Why is this medicine appropriate for me?
- How long will I need treatment?
- What side effects should I expect?
- Which side effects require urgent medical attention?
- Will the treatment affect my fertility?
- Do I need bone-density monitoring?
- What blood tests will I need?
- How will we know whether the treatment is working?
- What happens if the cancer stops responding?
- What will the estimated treatment cost be?
- Are generic alternatives appropriate?
- How often will I need follow-up?
Frequently asked questions
What is hormone therapy for cancer?
Hormone therapy is a cancer treatment that reduces hormone production or blocks hormones from stimulating hormone-sensitive cancer cells. It is particularly important in breast and prostate cancer.
Is hormone therapy effective?
Hormone therapy can be an important and effective treatment for cancers that depend on hormones for growth. Its benefit depends on the cancer type, hormone sensitivity, stage and individual disease biology.
Is hormone therapy a cure for cancer?
Not necessarily. In some early cancers, endocrine therapy is used to reduce the risk of recurrence after definitive treatment. In recurrent or metastatic disease, it may be used primarily for disease control. The objective varies from patient to patient.
How many years is hormone therapy given?
For hormone receptor-positive breast cancer, treatment commonly lasts at least five years, with longer treatment considered for selected patients. Prostate cancer treatment duration varies considerably according to disease stage and treatment strategy.
Can hormone therapy be taken at home?
Many hormone therapies are oral medicines that can be taken at home. Other treatments, including certain hormone injections, require administration by a healthcare professional.
Does hormone therapy require hospitalisation?
Usually, hormone therapy itself does not require prolonged hospitalisation. However, some injections, procedures or combination treatments may require a hospital visit.
Can hormone therapy be combined with radiation?
Yes. For example, selected patients with prostate cancer receive ADT together with radiation therapy. The combination depends on cancer risk and treatment objectives.
Can hormone therapy be combined with chemotherapy?
Yes, depending on the cancer and clinical setting. The treatment sequence or combination is determined by the oncology team.
Can hormone therapy stop working?
Yes. Some cancers eventually develop mechanisms that allow them to grow despite hormonal suppression. In prostate cancer, this may lead to castration-resistant disease. In breast cancer, endocrine resistance can also develop. When this happens, doctors may consider another endocrine treatment or another class of cancer treatment.
Does hormone therapy cause weight gain?
Some forms of endocrine treatment, particularly androgen deprivation for prostate cancer, can contribute to changes in body composition and weight. Lifestyle measures and medical monitoring can help manage these changes.
Is hormone therapy painful?
Most oral hormone therapies are not painful to take. Hormonal injections may cause temporary discomfort at the injection site. Some patients experience joint pain, hot flushes or other treatment-related symptoms.
Can hormone therapy affect sexual function?
Yes. Reduced libido and sexual-function changes can occur, particularly with androgen deprivation therapy and ovarian suppression. These concerns should be discussed openly with the oncology team because supportive treatments may be available.
Can hormone therapy be stopped suddenly?
Do not stop cancer hormone therapy without discussing it with your oncologist. Stopping treatment prematurely can reduce the intended benefit and may affect cancer control.
How much does hormone therapy cost in India?
GAF Healthcare partner planning is $1,000–$4,500, typically Outpatient · often years of tablets. Neighbouring United States comparison figures are $5,000–$25,000. The total depends on the medicine, duration, monitoring and whether another systemic treatment is added.
When should I go to an emergency department?
Chest pain, sudden breathlessness, one-sided leg swelling suggesting a clot, collapse, heavy unexpected bleeding, high fever or a rapidly worsening rash during treatment belongs in a local emergency department. Do not use WhatsApp as emergency care.
Can international patients start hormone therapy in India?
Yes, after records review. Feasibility depends on the cancer, receptor status, medicine availability and a plan for continuing tablets or injections at home.
Which city in India is right?
There is no single preferred city. Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad are live GAF catalog cities. Confirm the campus that can prescribe the named medicine and monitor bone, metabolic and cancer-specific markers.
Hormone therapy in India: key takeaways
- Breast and prostate cancers are the major cancers treated with hormone therapy.
- Breast cancer treatment commonly focuses on ER/PR status.
- Prostate cancer treatment commonly focuses on androgen suppression or androgen-receptor blockade.
- Hormone therapy may be used after surgery, before surgery in selected cases, with radiation, or for recurrent and metastatic disease.
- Treatment can last for months or several years depending on the cancer.
- Side effects are different from conventional chemotherapy and are often related to changes in hormone levels.
- Long-term treatment may require monitoring of bone, metabolic, cardiovascular or reproductive health, depending on the therapy.
- Hormone therapy is not the same as menopausal hormone replacement therapy.
- The most appropriate medicine depends on the patient’s cancer biology, stage, previous treatment and overall health.
- Patients travelling to India should send their pathology, imaging and treatment records before travelling whenever possible.
- GAF Healthcare partner planning is $1,000–$4,500, typically Outpatient · often years of tablets.
- Severe symptoms belong in a local emergency department, not on WhatsApp.
Final word
Hormone therapy has changed the way many hormone-sensitive cancers are managed. For the right patient, it can provide long-term cancer control while avoiding some of the toxicities associated with conventional chemotherapy.
But hormone therapy is not one treatment or one medicine. Tamoxifen, aromatase inhibitors, ovarian suppression, androgen deprivation and androgen-receptor-targeting medicines work through different mechanisms and are used in different clinical situations.
The right treatment therefore begins with an accurate diagnosis and a clear understanding of the cancer’s biology.
If you are considering hormone therapy in India, the most useful first step is to have your pathology, imaging and previous treatment records reviewed by a medical oncologist. A personalised treatment plan can then be developed around the type and stage of cancer rather than choosing a medicine based solely on its name or cost.
WhatsApp GAF Healthcare on +91 90443 46292 for a records review. Use a local emergency department for urgent symptoms.
Sources
- National Cancer Institute (NCI) — Hormone Therapy to Treat Cancer.
- National Cancer Institute (NCI) — Hormone Therapy for Breast Cancer.
- National Cancer Institute (NCI) — Hormone Therapy for Prostate Cancer.
- National Cancer Institute (NCI) — Prostate Cancer Treatment.
- National Cancer Institute (NCI) — Breast Cancer Treatment, Health Professional Version.
- American Cancer Society — Hormone Therapy for Breast Cancer.
- American Cancer Society — Hormone Therapy for Cancer.
- American Society of Clinical Oncology (ASCO) — Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer.
- Indian Council of Medical Research (ICMR) — Breast Cancer Consensus Guidance.
- ICMR, Government of India — Cancer Management Guidelines.
Treatment Process
- 1
Share records
The patient provides pathology, receptor or PSA reports and prior treatment summaries before anyone books travel.
- 2
Confirm hormone sensitivity
A medical oncologist reviews ER/PR/HER2, PSA, imaging and whether endocrine therapy can change the plan.
- 3
Name the treatment goal
The team decides whether the aim is recurrence reduction, neoadjuvant control, metastatic disease control or symptom relief.
- 4
Itemised estimate
GAF hormone-therapy planning is $1,000–$4,500. Neighbouring targeted therapy is $8,000–$30,000 if a matched medicine is later named.
- 5
Select the medicine
Tamoxifen, an aromatase inhibitor, ovarian suppression, ADT or an androgen-receptor medicine is chosen from the cancer biology.
- 6
Start and monitor
Tablets or injections begin with a written schedule for bone, metabolic, PSA or gynaecological monitoring.
- 7
Transfer home
Most patients continue tablets or scheduled injections at home after a stable plan is documented.
- 8
Review resistance
If the cancer progresses, the team considers another endocrine line or a different class of treatment.
